CYRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CY

Mkt Cap

$853.5M

Volume

508.98K

Next Earnings

November 3rd

Loading chart

CY

CYRXCryoPort, Inc. Common Stock

CYRX

Pay with—

Available Balance0.00

CY

Mkt Cap

$864.6M

Volume

508.98K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?CryoPort, Inc. (CYRX) has returned 81.3% year-to-date, significantly outperforming the Medical sector's 1.6% average return. The company holds a Zacks Rank #2 (Buy) with improving earnings outlook. Delcath Systems, Inc. (DCTH) has also outperformed with a 58.1% year-to-date return and a Zacks Rank #1 (Strong Buy), supported by an 80.7% increase in consensus EPS estimates over three months.Zacks Investment Research · Oct 1, 2026

Cryoport Reports First Quarter 2026 Financial ResultsCryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by strong performance in Life Sciences Services (18% growth) and Life Sciences Products (15% growth). Commercial CGT revenue grew 26% to $9.1 million, and the company supports a record 766 clinical trials and 21 approved therapies. The company raised full-year 2026 revenue guidance to $192-196 million and reported improved adjusted EBITDA from continuing operations.Benzinga · May 4, 2026

Biopharmaceutical Third Party Logistics (Distribution Management, Packaging & Labeling, Transportation, Warehousing) Market Research and Global Forecast Report 2026-2032The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.GlobeNewswire Inc. · Apr 9, 2026

Bio-Preservation Market to Reach US$ 44.45 Billion by 2035 | Cold Chain Expansion and Cell & Gene Therapy Commercialization Drive Growth Says Astute AnalyticaThe global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.GlobeNewswire Inc. · Feb 11, 2026

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 SeriesCryoport announced the launch of the MVE Fusion® 800 Series, a self-sustaining cryogenic freezer that eliminates the need for continuous liquid nitrogen supply. The compact system, recognized with the ISBER Outstanding New Product Award, is designed for space-constrained environments like medical research facilities, hospitals, and biorepositories, maintaining temperatures at or below -150°C.Benzinga · Feb 11, 2026

Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply ChainCryoport Systems has become the first global supply chain solutions company to achieve ISO 21973 certification, demonstrating its leadership in ensuring safe and traceable transportation of cell and gene therapies.Benzinga · Oct 30, 2025

Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, FranceCryoport Systems has launched a new 55,000-square-foot global supply chain center near Paris, France, expanding its network to support complex life sciences supply chain needs, including biologistics and bioservices.Benzinga · Oct 1, 2025

Clinical Trial Biorepository and Archiving Solutions Market Size Expected to Attain USD 9.69 Billion by 2034The global clinical trial biorepository and archiving solutions market is projected to grow from USD 4.76 billion in 2025 to USD 9.69 billion by 2034, with a CAGR of 8.21%. North America dominates the market, while Asia Pacific is expected to experience the fastest growth, driven by advancements in biobanking technologies and increasing demand for personalized medicine.GlobeNewswire Inc. · Aug 19, 2025

CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX)Cryoport CEO Jerrell Shelton exercised and sold 16,344 shares at $7.06 per share, retaining 928,763 shares. The company continues to face financial challenges with recent revenue drops and ongoing losses.The Motley Fool · Jun 30, 2025

Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025Cryoport, a global provider of supply chain solutions for the life sciences sector, will report its first quarter 2025 financial results on May 7, 2025. The company will host a conference call to discuss the results.Benzinga · Apr 24, 2025

to start trading

CY

CYRXCryoPort, Inc. Common Stock

CYRX

Pay with—

Available Balance0.00

Your PositionYou don't own any CYRX yet.

Related Tickers

Earnings